Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis
暂无分享,去创建一个
[1] C. Dye,et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru , 2002, The Lancet.
[2] Brian G. Williams,et al. Erasing the World's Slow Stain: Strategies to Beat Multidrug-Resistant Tuberculosis , 2002, Science.
[3] W. Lew,et al. Ambulatory treatment of multidrug-resistant pulmonary tuberculosis patients at a chest clinic. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[4] Rajesh K. Gupta,et al. Responding to Market Failures in Tuberculosis Control , 2001, Science.
[5] L. Karasulu,et al. The treatment of multidrug-resistant tuberculosis in Turkey. , 2001, The New England journal of medicine.
[6] Christopher Dye,et al. Global trends in resistance to antituberculosis drugs. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. , 2001, The New England journal of medicine.
[7] Low rate of emergence of drug resistance in sputum positive patients treated with short course chemotherapy. , 2001, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[8] A. Aerts,et al. DOTS and DOTS plus: what's in a name. , 2001, The International Journal of Tuberculosis and Lung Disease.
[9] P. Farmer,et al. Public health. Responding to market failures in tuberculosis control. , 2001, Science.
[10] Reichman Lb,et al. DOTS and DOTS plus: what's in a name. , 2000 .
[11] A. Khomenko,et al. Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries. , 2000, JAMA.
[12] T. Frieden,et al. The status and prospects of tuberculosis control in India. , 2000, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[13] Christopher Dye,et al. Global burden of tuberculosis , 1999 .
[14] C. Dye,et al. Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. , 1999, JAMA.
[15] C. Dye,et al. Rational 'DOTS plus' for the control of MDR-TB. , 1999, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[16] Jim Y. Kim,et al. Community based approaches to the control of multidrug resistant tuberculosis: introducing “DOTS-plus” , 1998, BMJ.
[17] H L Rieder,et al. Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance. , 1998, The New England journal of medicine.
[18] G. Peersman,et al. A survey of drug-resistant Mycobacterium tuberculosis and its relationship to HIV infection. , 1998 .
[19] S. Weis,et al. A survey of drug‐resistant Mycobacterium tuberculosis and its relationship to HIV infection , 1998, AIDS.
[20] Global Tuberculosis Programme. Global tuberculosis control : WHO report , 1997 .
[21] S. A. Abdool Karim,et al. Multidrug-resistant tuberculosis in patients without HIV infection. , 1996, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.
[22] F. Portaels,et al. Impact of short-course therapy on tuberculosis drug resistance in South-West Burkina Faso. , 1996, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[23] Salim Yusuf,et al. Risk factors for acute myocardial infarction in Indians: a case-control study , 1996, The Lancet.
[24] Christopher J. L. Murray. Results of directly observed short-course chemotherapy in 112 842 Chinese patients with smear-positive tuberculosis , 1996, The Lancet.
[25] T. Frieden,et al. Emergence of fluoroquinolone-resistant tuberculosis in New York City , 1995, The Lancet.
[26] L. Ackerson,et al. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. , 1993, The New England journal of medicine.
[27] D. Mitchison,et al. Influence of initial drug resistance on the response to short-course chemotherapy of pulmonary tuberculosis. , 2015, The American review of respiratory disease.
[28] S. Pauker,et al. The Markov Process in Medical Prognosis , 1983, Medical decision making : an international journal of the Society for Medical Decision Making.
[29] K. Stýblo,et al. Recent advances in epidemiological research in tuberculosis. , 1982, Advances in tuberculosis research. Fortschritte der Tuberkuloseforschung. Progres de l'exploration de la tuberculose.
[30] B. Thompson. Survival Rates in Pulmonary Tuberculosis , 1943, British medical journal.
[31] G. J. Drolet,et al. Present Trend of Case Fatality Rates in Tuberculosis. , 1938 .